National Association of Professional Women Announces Diana Wood, R.N., B.S.N., VP, Corporate Development at Stason Animal Health, as a 2014 Professional Woman of the Year

Share Article

Diana Wood is recognized as an NAPW VIP Woman of the Year for her outstanding leadership and commitment within her profession

NAPW honors Diana Wood, R.N., B.S.N., VP, Corporate Development for Stason Animal Health, Inc., as a 2014 Professional Woman of the Year. Ms. Wood is recognized with this prestigious distinction for leadership in clinical development. As the largest organization of women in the country, spanning virtually every industry and profession, the National Association of Professional Women is a powerfully vibrant networking community with over 600,000 members and more than 400 Local Chapters.

Diana Wood is a 19-year clinical development veteran whose previous employers included IVAC Corporations, Block Medical, Medication Delivery Devices, Maxim Pharmaceuticals, Chugai Pharmaceuticals and Chiltern International.

For the last six years, Ms. Wood has been in many areas within Stason Animal Health (SAH) and in many positions. Previous to her present position as VP of Corporate Development with SAH, she was the VP of Business Development for Stason Pharmaceuticals. She is currently VP, Corporate Development through her consultant company, Strategic Pharma, LLC. Stason Pharmaceuticals, Inc. is involved in the development and manufacturing of oncology generic drugs for humans.

In the summer of 2013, Ms. Wood took over Stason Animal Health and CK9, LLC (CK9) as CEO and relocated to these businesses from Vancouver Washington to Kansas City, the hub of animal health development. Both companies are involved in the development of new drugs for companion animals and are majority owned by Stason Pharmaceuticals, Inc.

After the formation of KCSpecialty Therapeutics, LLC (KCST) Ms. Wood took over as CEO. KCST is a wholy owned subsidiary of Stason Pharmaceuticals and is focused on the development and licensing of orphan drugs for human development. KCST recently signed a $15 million deal with a Japanese partner to develop a new chemical entity that was previously granted Orphan Drug Designation. Pre-clinical studies are starting this year.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lisa Mancuso
+1 516-4536111
Email >

Diana Wood
Stason Animal Health, Inc.
Email >